Moreover, with very little information in the public domain, keeping track of the environment can be incredibly difficult. Global teams need to make sure that their evidence packages are in line with what’s happening locally on the ground. But how do you do that when your situation analysis is restricted by poor visibility? Success requires a different approach.
In many parts of the world, particularly Europe, market access processes are typically framed around health technology assessments (HTAs). In the UK, for example, teams can almost “isolate” NICE and configure their market access programs around a clearly defined HTA roadmap. In Asian markets, however, this isn’t an option. The links between price, HTA, reimbursement, and regulatory are so pronounced that you have to look at the whole system. This, in turn, requires cross-functional alignment across all market access disciplines. Old-fashioned silo working is a major barrier to agile and efficient market access strategies. Integration and collaboration are crucial.
Fundamentally, market access in APAC is a broad and complex jigsaw. Completing it requires joined-up thinking to see the bigger picture and understand how all the pieces fit together.
Read the full article on the PRMA Consulting website